ATE500752T1 - Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom - Google Patents

Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom

Info

Publication number: ATE500752T1
Authority: AT; Austria
Prior art keywords: treatment; insulin resistance; sphingolipids; prevention; type
Prior art date: 2004-03-16

Application number

AT05722048T

Other languages

English (en)

Inventor

Willem Nieuwenhuizen

Aloysius Havekes

Josephus Emeis

Original Assignee

Tno

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-16

Filing date

2005-03-15

Publication date

2011-03-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34975255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE500752(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-03-16 Priority claimed from EP04075848A external-priority patent/EP1576894A1/de

2005-03-15 Application filed by Tno filed Critical Tno

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE500752T1 publication Critical patent/ATE500752T1/de

Links

208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 5
206010022489 Insulin Resistance Diseases 0.000 title abstract 3
150000003408 sphingolipids Chemical class 0.000 title abstract 3
230000002265 prevention Effects 0.000 title abstract 2
230000004060 metabolic process Effects 0.000 title 1
208000011580 syndromic disease Diseases 0.000 title 1
125000000923 (C1-C30) alkyl group Chemical group 0.000 abstract 2
208000001145 Metabolic Syndrome Diseases 0.000 abstract 2
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
150000001323 aldoses Chemical class 0.000 abstract 1
125000003368 amide group Chemical group 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 abstract 1
235000015872 dietary supplement Nutrition 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 abstract 1
229920001223 polyethylene glycol Polymers 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
150000003141 primary amines Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 abstract 1
150000005846 sugar alcohols Chemical class 0.000 abstract 1
229910021653 sulphate ion Inorganic materials 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nutrition Science (AREA)
Polymers & Plastics (AREA)
Hematology (AREA)
Food Science & Technology (AREA)
Mycology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Botany (AREA)
Oil, Petroleum & Natural Gas (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT05722048T 2004-03-16 2005-03-15 Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom ATE500752T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04075848A EP1576894A1 (de)	2004-03-16	2004-03-16	Verwendung von Sphingolipiden zur Behandlung und Prävention von TYP 2 DIABETES, Insulinresistenz und METABOLISCHEN SYNDROMS
EP04077088		2004-07-19
PCT/NL2005/000193 WO2005087023A1 (en)	2004-03-16	2005-03-15	The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome

Publications (1)

Publication Number	Publication Date
ATE500752T1 true ATE500752T1 (de)	2011-03-15

Family

ID=34975255

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05722048T ATE500752T1 (de)	2004-03-16	2005-03-15	Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom

Country Status (7)

Country	Link
US (3)	US20070207983A1 (de)
EP (1)	EP1729597B1 (de)
JP (1)	JP5154218B2 (de)
AT (1)	ATE500752T1 (de)
AU (1)	AU2005220692A1 (de)
DE (1)	DE602005026785D1 (de)
WO (1)	WO2005087023A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6262118B1 (en) *	1999-06-04	2001-07-17	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) *	1999-06-04	2009-08-18	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
EP1811991B1 (de) *	2004-11-10	2018-11-07	Genzyme Corporation	Behandlung von Typ 2 Diabetes mit Inhibitoren der Glycosphigolipid-Synthese
SI2032134T1 (sl)	2006-05-09	2015-10-30	Genzyme Corporation	Postopki zdravljenja bolezni zamaščenih jeter, ki obsegajo inhibicijo sintezo glukosfingolipida
JP2007320901A (ja)	2006-05-31	2007-12-13	Snow Brand Milk Prod Co Ltd	内臓脂肪蓄積抑制剤及び、血中アディポネクチン濃度増加促進及び／又は減少抑制剤
EP2594564B1 (de)	2007-05-31	2016-09-28	Genzyme Corporation	Glukosylceramid-Synthase-Hemmer vom 2-Acylaminpropanol-Typ
CN101888840A (zh)	2007-10-05	2010-11-17	简詹姆公司	使用脑酰胺衍生物治疗多囊性肾疾病的方法
CA2731685A1 (en)	2008-07-28	2010-02-04	Genzyme Corporation	Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP3078373A1 (de)	2008-10-03	2016-10-12	Genzyme Corporation	Glucosylceramidsynthaseinhibitoren vom 2-acylaminoanoltyp
CA2739787A1 (en) *	2008-10-08	2010-04-15	Nucitec S.A. De C.V.	.beta.-hydroxy-.gamma.-aminophosphonates and methods for the preparation and use thereof
WO2010131718A1 (ja) *	2009-05-13	2010-11-18	丸大食品株式会社	鳥皮由来スフィンゴミエリン含有物を有効成分とする抗高血糖及び／又は抗高脂血症剤
JP6169978B2 (ja) *	2012-01-25	2017-07-26	株式会社Ｊ−オイルミルズ	スフィンゴイド塩基を含む抽出物の製造方法
US9492466B2 (en)	2012-06-14	2016-11-15	Nucitec S.A. De C.V.	Beta-hydroxy-gamma-aminophosphonates for treating immune disorders
WO2018075622A1 (en) *	2016-10-19	2018-04-26	University Of Miami	Materials and methods for modulating insulin signaling and preserving podocyte function
US10799564B1 (en)	2019-05-06	2020-10-13	Baxter International Inc.	Insulin premix formulation and product, methods of preparing same, and methods of using same
US20220409617A1 (en) *	2019-11-13	2022-12-29	The Regents Of The University Of California	Drug Formulations and Methods of Treatment for Metabolic Disorders

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4952567A (en) *	1988-05-09	1990-08-28	City Of Hope	Inhibition of lipogenesis
IT1235162B (it) *	1988-12-02	1992-06-22	Fidia Farmaceutici	Derivati di lisosfingolipidi
US5190876A (en) *	1988-12-27	1993-03-02	Emory University	Method of modifying cellular differentiation and function and compositions therefor
US5130333A (en) *	1990-10-19	1992-07-14	E. R. Squibb & Sons, Inc.	Method for treating type II diabetes employing a cholesterol lowering drug
JP3157531B2 (ja) *	1991-03-08	2001-04-16	昭和産業株式会社	血中コレステロール低下剤
US5232837A (en) *	1991-08-05	1993-08-03	Emory University	Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination
US5374616A (en) *	1991-10-18	1994-12-20	Georgetown University	Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
US6190894B1 (en) *	1993-03-19	2001-02-20	The Regents Of The University Of California	Method and compositions for disrupting the epithelial barrier function
US5478860A (en) *	1993-06-04	1995-12-26	Inex Pharmaceuticals Corp.	Stable microemulsions for hydrophobic compound delivery
US5830853A (en) *	1994-06-23	1998-11-03	Astra Aktiebolag	Systemic administration of a therapeutic preparation
US6773719B2 (en) *	1994-03-04	2004-08-10	Esperion Luv Development, Inc.	Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US20020182250A1 (en) *	1995-09-06	2002-12-05	Goro Hori	Lipid metabolism improving agent
EP0888458A4 (de) *	1996-02-20	2004-05-06	Sloan Kettering Institutefor C	Kombination von pkc-inhibitoren und therapeutischen agenzien zur behandlung von krebs
JP3495740B2 (ja) *	1997-04-10	2004-02-09	麒麟麦酒株式会社	α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤
US6800661B1 (en) *	1997-04-15	2004-10-05	Board Of Trustees Of The University Of Illinois	Spisulosine compounds
US5989803A (en) *	1997-09-05	1999-11-23	The Trustees Of Columbia University In The City Of New York	Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
US6492337B1 (en) *	1997-12-30	2002-12-10	A+ Science Ab	Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complication
DE69943314D1 (de) *	1998-02-12	2011-05-12	Kapil N Bhalla	Sphingolipid-derivate und verfahren zu deren verwendung
AU776785B2 (en) *	1999-02-24	2004-09-23	Johns Hopkins University, The	Compositions and methods for modulating serum cholesterol
WO2001003739A1 (fr) *	1999-07-12	2001-01-18	Ono Pharmaceutical Co., Ltd.	Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
JP2001213858A (ja) *	1999-11-24	2001-08-07	Sagami Chem Res Center	スフィンゴシン誘導体
JP2003523336A (ja) *	2000-02-18	2003-08-05	メルクエンドカムパニーインコーポレーテッド	糖尿病及び脂質障害のためのアリールオキシ酢酸
AU2001255199A1 (en) *	2000-03-28	2001-10-08	The Liposome Company, Inc.	Ceramide derivatives and method of use
US6949247B2 (en) *	2000-12-28	2005-09-27	Unilever Home & Personal Care Usa Division Of Conopco, Inc.	Stable skin care compositions containing a retinoid and a retinoid booster system
JP2002226394A (ja) *	2001-02-01	2002-08-14	Meiji Milk Prod Co Ltd	脂質代謝改善組成物
JP4958339B2 (ja) *	2001-03-21	2012-06-20	雪印メグミルク株式会社	脂質代謝改善剤
CN102319266B (zh) *	2001-06-18	2014-12-17	海王星技术&生物资源有限公司	用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物
US20030109044A1 (en) *	2001-10-16	2003-06-12	Millennium Pharmaceuticals, Inc.	Methods of using 279, a human G protein-coupled protein receptor
JP4568464B2 (ja) *	2001-11-07	2010-10-27	雪印乳業株式会社	記憶障害予防治療剤
JP2006507223A (ja) *	2002-05-17	2006-03-02	エスペリオンセラピューティクス，インコーポレイテッド	脂質代謝異常疾患の治療方法
EP1585508B1 (de) *	2003-01-20	2009-04-01	Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO	Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.
JP4585172B2 (ja) *	2003-01-31	2010-11-24	森永乳業株式会社	骨形成促進剤
US9717754B2 (en) *	2003-02-27	2017-08-01	Enzo Therapeutics, Inc.	Glucocerebroside treatment of disease
JP4341891B2 (ja) *	2003-03-05	2009-10-14	森永乳業株式会社	血糖降下組成物
AU2003217508A1 (en) *	2003-03-07	2004-09-28	Korea Atomic Energy Research Institute	A composition comprising phytosphingosine or a derivative thereof

2005
- 2005-03-15 AU AU2005220692A patent/AU2005220692A1/en not_active Abandoned
- 2005-03-15 DE DE602005026785T patent/DE602005026785D1/de not_active Expired - Lifetime
- 2005-03-15 WO PCT/NL2005/000193 patent/WO2005087023A1/en not_active Ceased
- 2005-03-15 JP JP2007503852A patent/JP5154218B2/ja not_active Expired - Fee Related
- 2005-03-15 EP EP05722048A patent/EP1729597B1/de not_active Revoked
- 2005-03-15 US US10/592,994 patent/US20070207983A1/en not_active Abandoned
- 2005-03-15 AT AT05722048T patent/ATE500752T1/de not_active IP Right Cessation
2009
- 2009-02-11 US US12/369,322 patent/US20090203651A1/en not_active Abandoned
2010
- 2010-09-17 US US12/884,607 patent/US20110003772A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE602005026785D1 (de)	2011-04-21
AU2005220692A1 (en)	2005-09-22
US20090203651A1 (en)	2009-08-13
US20070207983A1 (en)	2007-09-06
JP2007529507A (ja)	2007-10-25
US20110003772A1 (en)	2011-01-06
EP1729597A1 (de)	2006-12-13
JP5154218B2 (ja)	2013-02-27
EP1729597B1 (de)	2011-03-09
WO2005087023A1 (en)	2005-09-22

Legal Events

Date	Code	Title	Description
2011-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE500752T1 (de)	2011-03-15	Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom
TW200602043A (en)	2006-01-16	Use of indazolecarboxamide derivatives for preparing a medicinal product intended for the treatment and prevention of malaria
MY148566A (en)	2013-04-30	Crystalline solvates and complexes of (is) -1, 5- anhydro-1 -c-(3-( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
TW200730540A (en)	2007-08-16	Novel peptide compounds
TW200744659A (en)	2007-12-16	Preparation for preventing and ameliorating wrinkle
BRPI0517803A (pt)	2008-10-21	pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
MY142807A (en)	2011-01-14	Benzimidazole derivative and use thereof.
DE502004002556D1 (de)	2007-02-15	Tripeptide und deren derivate für die kosmetische verwendung zur verbesserung der hautstruktur
BR0317703A (pt)	2005-11-22	Composto, formulação farmacêutica, uso de um composto, processo para a preparação de compostos, e, intermediários
WO2008019266A3 (en)	2008-11-13	Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
MX2007010532A (es)	2007-10-12	Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
MX2009003073A (es)	2009-04-02	Derivado de 2-piridincarboxamida que tiene efecto activador de gk.
MY151295A (en)	2014-04-30	Pyrimidyl indoline compound
MY151072A (en)	2014-03-31	Heteroaryl derivative
TW200724136A (en)	2007-07-01	Pharmaceutical compositions comprising PPAR modulator
DE602004030004D1 (de)	2010-12-23	Verbindungen zur behandlung von stoffwechselstörungen
ATE391730T1 (de)	2008-04-15	Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung
GEP20104882B (en)	2010-01-11	Age inhibitors
TW200714598A (en)	2007-04-16	Urea derivatives, methods for their manufacture, and uses therefor
TW200744589A (en)	2007-12-16	Pharmaceutical composition
AR044175A1 (es)	2005-08-24	Compuestos de cefemo
EP2055188A4 (de)	2010-02-10	Polyphenolgehaltsteigerndes mittel für pflanze
WO2007033039A3 (en)	2007-10-04	Proteasome inhibiting beta lactam compounds
MX2009006094A (es)	2009-08-25	Uso de derivados canfolenicos como ingredientes fragantes en perfumeria y saborizacion.
MX2009004006A (es)	2009-04-28	Derivados de indol novedosos, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen.